BioSense Global 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Antiferon (interferon alpha kinoid) / Neovacs
ChiCTR2000035633: Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK/PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients

Not yet recruiting
N/A
32
 
Atomization treatment, 0.2mg IFN-k/ 0.5 mg TFF2 ;Atomization treatment, 1mg IFN-k/ 2.5 mg TFF2 ;Atomization treatment, 2mg IFN-κ/ 5 mg TFF2 ;Atomization treatment, 4mg IFN-κ/ 10 mg TFF2
Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center, Shanghai Public Health Clinical Center
Novel Coronavirus Pneumonia (COVID-19)
 
 

Download Options